MedPath

Clinical trail of NRL/2019/NL in Liver Disorder Patients with Abnormal Liver Function Test

Phase 1
Conditions
Health Condition 1: K769- Liver disease, unspecified
Registration Number
CTRI/2020/01/023033
Lead Sponsor
etsurf Communications Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Males or females 18-65 years of age

Diagnosis of hepatic disorder with abnormal LFT with or without signs and symptoms such as dark-colored urine, light-colored stools, pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, and right upper abdominal discomfort, pain

Subjects with or without fatty liver changes observed in Ultrasonography of abdomen will be enrolled in the study

Serum total bilirubin level less than or equal to 2 mg/dl, or AST or ALT 2 times than normal values

Subjects willing to sign inform consent form

Exclusion Criteria

Evidence of chronic viral hepatitis (Hepatitis B or C) and Biliary obstruction

Previous entry into the study, or use of either prednisolone or PTX within 6 weeks of admission

AST >500 U/L or ALT >300 U/L

Suspected hypersensitivity to contents of study drug

Advanced liver disease, subjects with serious illness

History of gastritis, peptic ulcer, bleeding ulcer

Patients with a renal failure

Pregnant or lactating women

Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath